The Fort Worth Press - Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

USD -
AED 3.672501
AFN 63.495489
ALL 83.192586
AMD 375.730804
ANG 1.790083
AOA 916.999989
ARS 1383.990646
AUD 1.452226
AWG 1.8
AZN 1.697632
BAM 1.693993
BBD 2.007535
BDT 122.298731
BGN 1.709309
BHD 0.376597
BIF 2960.807241
BMD 1
BND 1.28353
BOB 6.91265
BRL 5.2553
BSD 0.996752
BTN 94.473171
BWP 13.741284
BYN 2.966957
BYR 19600
BZD 2.004591
CAD 1.387005
CDF 2282.496424
CHF 0.795017
CLF 0.023433
CLP 925.259734
CNY 6.91185
CNH 6.92068
COP 3662.985579
CRC 462.864319
CUC 1
CUP 26.5
CVE 95.504742
CZK 21.2958
DJF 177.489065
DKK 6.492703
DOP 59.330475
DZD 133.010264
EGP 52.781589
ERN 15
ETB 154.083756
EUR 0.866103
FJD 2.257405
FKP 0.752712
GBP 0.750441
GEL 2.679862
GGP 0.752712
GHS 10.921138
GIP 0.752712
GMD 73.500634
GNF 8739.335672
GTQ 7.62808
GYD 208.64406
HKD 7.82615
HNL 26.46399
HRK 6.5452
HTG 130.656966
HUF 338.089034
IDR 16990.8
ILS 3.13762
IMP 0.752712
INR 94.850202
IQD 1305.703521
IRR 1313250.000216
ISK 124.760128
JEP 0.752712
JMD 156.892296
JOD 0.708974
JPY 160.287037
KES 129.470356
KGS 87.450219
KHR 3992.031527
KMF 428.0001
KPW 900.00296
KRW 1508.000246
KWD 0.30791
KYD 0.830627
KZT 481.867394
LAK 21678.576069
LBP 89256.247023
LKR 313.975142
LRD 182.893768
LSL 17.115586
LTL 2.95274
LVL 0.60489
LYD 6.362652
MAD 9.315751
MDL 17.507254
MGA 4153.999394
MKD 53.388766
MMK 2098.832611
MNT 3571.142668
MOP 8.042181
MRU 39.797324
MUR 46.77056
MVR 15.449908
MWK 1728.292408
MXN 18.140005
MYR 3.923953
MZN 63.950136
NAD 17.115586
NGN 1383.460041
NIO 36.680958
NOK 9.702861
NPR 151.156728
NZD 1.737333
OMR 0.38408
PAB 0.996752
PEN 3.472089
PGK 4.307306
PHP 60.549842
PKR 278.184401
PLN 3.72091
PYG 6516.824737
QAR 3.634057
RON 4.427298
RSD 101.684639
RUB 81.511073
RWF 1455.545451
SAR 3.752751
SBD 8.042037
SCR 15.03876
SDG 601.000048
SEK 9.47367
SGD 1.292698
SHP 0.750259
SLE 24.55019
SLL 20969.510825
SOS 569.659175
SRD 37.601032
STD 20697.981008
STN 21.220389
SVC 8.721147
SYP 110.527654
SZL 17.114027
THB 32.495002
TJS 9.523624
TMT 3.5
TND 2.938634
TOP 2.40776
TRY 44.440189
TTD 6.772336
TWD 32.044406
TZS 2571.564679
UAH 43.689489
UGX 3713.134988
UYU 40.344723
UZS 12155.385215
VES 467.928355
VND 26337.5
VUV 119.385423
WST 2.775484
XAF 568.149495
XAG 0.014291
XAU 0.000222
XCD 2.70255
XCG 1.796371
XDR 0.706596
XOF 568.149495
XPF 103.295656
YER 238.601083
ZAR 17.089659
ZMK 9001.202399
ZMW 18.763154
ZWL 321.999592
  • RBGPF

    -13.5000

    69

    -19.57%

  • RELX

    -0.1000

    31.97

    -0.31%

  • NGG

    -0.4800

    81.92

    -0.59%

  • CMSC

    -0.0500

    22.77

    -0.22%

  • CMSD

    -0.0900

    22.66

    -0.4%

  • BCE

    -0.2200

    25.25

    -0.87%

  • BCC

    0.1400

    74.43

    +0.19%

  • RYCEF

    -0.5900

    14.65

    -4.03%

  • RIO

    0.8500

    86.64

    +0.98%

  • VOD

    -0.1400

    14.49

    -0.97%

  • JRI

    -0.2700

    11.8

    -2.29%

  • GSK

    -0.1000

    53.84

    -0.19%

  • AZN

    5.0200

    188.42

    +2.66%

  • BTI

    0.3749

    57.8

    +0.65%

  • BP

    0.5100

    46.68

    +1.09%

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

  • First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience

Text size:

ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Aspire's e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various configurations.

"We are excited to launch our new BUZZ BOMB™ e-commerce website in the U.S., which marks a significant step forward for the brand and will provide consumers with a seamless and personalized shopping experience," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "This launch enables us to offer our advanced sublingual pre-workout supplement-designed to help athletes and fitness enthusiasts maximize their performance potential -directly to customers across the nation and at a competitive price. Together with our significant presence and marketing plans at two of the largest fitness conventions in early August, we are confident that the launch of our e-commerce site will further accelerate the brand's growth among active and fitness-minded consumers, helping us achieve our goal of providing one of the most advanced caffeine delivery formulas on the market."

Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. BUZZ BOMB™, offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue-without any mixing with water or hassle--for immediate effect.

About the Aspire Targeted Oral Delivery Platform

Aspire's technology delivers fast-acting supplement formulations which have been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.



View the original press release on ACCESS Newswire

M.Delgado--TFWP